- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573907
Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg
Comparative Bioavailability Study of Levothyroxine Sodium Tablets 100 mcg in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Levothyroxine (T4) is used to treat patients with hypothyroidism and may often result in lifelong therapy. Its physiologically active metabolite is tri-iodothyronine (T3). Levothyroxine is also endogenously produced in the body. Since small changes in levothyroxine administration (e.g. change in brand or formulation) can cause significant changes in serum thyroid stimulating hormone (TSH) concentrations, precise and accurate TSH control is critical to avoid potential adverse iatrogenic effects. Tecnoquimicas modified its Levothyroxine tablets formulation in order to comply with new pharmacopeial specifications. It will then evaluate the impact on drug product performance based on pharmacokinetic (PK) measures of total serum T4 and total serum T3 of the new formulation of levothyroxine (Test formulation) relative to the reference formulation from Merck (Reference formulation)
This will be a single-center, open-label, two-period, two-treatment, two-sequence, randomized, single-dose, crossover study. 80 healthy adults will be randomized to receive a single dose (6 x 100 mcg tablets = 600 mcg) of the test formulation of levothyroxine and reference formulation of levothyroxine separately in each treatment period. There will be two treatment sequences (AB, BA) and a 42 day washout between the two treatment periods.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Entre Ríos
-
Paraná, Entre Ríos, Argentina
- DominguezLab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent
- Healthy volunteers according to antecedents, clinical evaluation, biochemical tests and other complimentary tests
- Sex: both (male and female, homogenously distributed)
- Age: 18 to 50 years old
- BMI: 18 to 30 kg/m2
- Non smokers from at least 3 months
Exclusion Criteria:
- History of liver disease, kidney disease or conditions of psychiatric origin.
- History of drug or alcohol abuse in the last two years.
- Ingestion of other drugs the 2 weeks prior to the start of the study.
- History of seizure disorders, depressive disorders, cardiovascular diseases, hematological, metabolic, vesicular or other, that the Principal Investigator judges clinically significant.
- Abnormal electrocardiogram (EKG).
- Hypersensitivity to Levothyroxine sodium or to excipients (from formulations to test).
- Positive HIV test; hepatitis B and C.
- Positive urine drug dose of abuse.
- Having participated in another research study in the last 6 months.
- Having donated blood within the 3 months prior to the start of the study.
- Clinically significant abnormal laboratory test results.
- Abnormal results outside the reference values for thyroid function (T3, T4, TSH, anti-TPO antibodies).
- Female volunteers who are breastfeeding during the study period.
- Positive beta-HCG test in female volunteers.
- Volunteers who must start a scheduled medical or pharmacological treatment outside the this Protocol.
- Volunteers who do not maintain the conditions of fasting and food intake in the pre-established schedules.
- Volunteers who do not avoid the intake of coffee, tea, grapefruit, cola and / or alcoholic beverages during the 48 h preceding the study.
- Volunteers on a special diet in the last 28 days (eg vegetarian diet, etc.).
- Volunteers with clinically significant allergies to food, medication, etc.
- Non-cooperative volunteers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test Formulation of Levothyroxine
Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
|
Administration of a 600 mcg levothyroxine dose
|
Active Comparator: Reference formulation of Levothyroxine
Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
|
Administration of a 600 mcg levothyroxine dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(AUC) Area Under the Curve 0-48 for T4
Time Frame: [Time Frame: From 0 to 48 hours]
|
-30 min., -15 min., 0 hour (h ) pre-dose; 30 min., 1 h, 1.30 h, 2 h, 2.30 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h , 48 hours
|
[Time Frame: From 0 to 48 hours]
|
(Cmax) Maximum concentration 0-48 for T4
Time Frame: [Time Frame: From 0 to 48 hours]
|
-30 min., -15 min., 0 hour ( h) pre-dose; 30 min., 1 h, 1.30 h, 2 h, 2.30 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h , 48 hours
|
[Time Frame: From 0 to 48 hours]
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PRO-BEQ-LEVO-007-V.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Drug Levothyroxine 100 mcg
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Protalex, Inc.CompletedArthritis, RheumatoidUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Al-Kindy College of MedicineAl-Elwyiah Maternity Teaching HospitalCompletedThyroid Diseases | Recurrent Early Pregnancy LossIraq
-
DBV TechnologiesActive, not recruitingPeanut AllergyUnited States, Canada, Australia, France, Germany, United Kingdom, Ireland, Netherlands
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Netherlands, France, Canada, Poland
-
Merck KGaA, Darmstadt, GermanyTerminatedIsolated Cartilage Injury of the KneeGermany
-
Janssen Pharmaceutical K.K.Completed
-
Sunovion Respiratory Development Inc.Completed